Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics announced the publication of Phase 1 results for ALLO-316, an allogeneic CAR T therapy targeting CD70 in metastatic renal cell carcinoma (RCC). The TRAVERSE study demonstrated a confirmed response rate of 31% in patients with high CD70 expression, with durable remissions persisting 8 to over 18 months and manageable safety pro…